Skip to content

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
- Overview
- Pipeline
Contact

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
- Overview
- Pipeline
Contact

paper

Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma

By Graviton / 04/2023

Clinical Cancer Research

FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models

By Graviton / 09/2022

Scientific Reports

Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer

By Graviton / 07/2022

Nature Communications

Therapeutic efficacy of FASN inhibition in preclinical models of HCC

By Graviton / 01/2022

Hepatology

TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial

By Graviton / 07/2021

Gastroenterology

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

By Graviton / 04/2021

EClinicalMedicine

Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities

By Graviton / 07/2020

Hepatology 2020

Fatty Acid Synthase – Modern Tumor Cell Biology Insights into a Classical Oncology Target

By natalia / 02/2017

Pharmacology and Therapeutics

FASN inhibition and taxane treatment combine to enhance anti-tumor efficacy in diverse xenograft tumor models through disruption of tubulin palmitoylation and microtubule organization and FASN inhibition-mediated effects on oncogenic signaling and gene expression

By natalia / 12/2016

EBioMedicine

DeNovo Palmitate Synthesis Supports Oncogenic Signaling Through Diverse Mechanisms: Implications for FASN-Targeted Therapeutics

By natalia / 08/2016

Journal of Cell Signaling

Post pagination

Site map

About
Science
Investors
Programs
Contact

About
Science
Investors
Programs
Contact

Contact us

Business Development
bd@sagimet.com

Investors
ir@sagimet.com

Media
media@sagimet.com

Human Resources
hr@sagimet.com

© 2024 Sagimet Biosciences. All Rights Reserved. Terms of Use Agreement | Privacy Policy | Clinical Trial Privacy Notice

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
- Overview
- Pipeline
Contact

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
- Overview
- Pipeline
Contact

Scroll to Top